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Abstract
Background: Adult patients with an esophageal cancer can potentially be compromised with postoperative leaks or fistulae if
patients’ nutritional status is in a vulnerable stage. Currently in Australia, there is a growing need for clinicians to know whether
use of immune-enhancing formulas (IEFs) containing Arg, omega-3, and RNA are a cost-effective approach compared with
isonitrogenous-isocaloric formulas to reduce postoperative infectious complications in esophagectomy patients. Since IEFs may
carry higher costs, this has led to inconsistencies in practice among clinicians and hospitals.
Objective: Our aim is to compile and present the most up-to-date nutrition evidence available regarding the provision of IEFs
containing Arg, omega-3, and RNA to help clinicians develop an evidence-based nutrition care plan; identify available evidence
of whether an esophagectomy patient should receive IEF; determine the cost-effectiveness and safety of such nutrition; and
determine appropriate administration quantity and timing (pre-, peri-, or postesophagectomy).
Methods: This review will include RCTs involving the use of IEFs enriched with Arg, omega-3 polyunsaturated fatty acids,
and RNA in the pre-, peri-, or postoperative period (for at least 5-7 days) given orally or via enteral feeding tube, in adult cancer
patients undergoing esophageal resection. Lower gastrointestinal, gastric, or head cancer surgery with parenteral nutrition or
non-IEF or use of isolated immunonutrient (Arg vs omega-3 vs RNA) will be excluded. Primary outcome comprises postoperative
infectious complications. Secondary outcomes (pre/postoperatively) consist of cost-effectiveness, length of stay, survival/mortality,
quality of life, nutritional status, percentage of weight loss, and biochemical changes. The risk of bias will be independently
assessed by the reviewers, using a domain-based evaluation tool. Blinding will be assessed for subjective and objective outcome
measures. Publication bias will be visually assessed by funnel plots. A meta-analysis will be generated by the Review Manager
5.3 software and represented in forest plots.
Results: The first results are expected in 2018. Outlining the protocol will ensure transparency for the completed review.
Conclusions: This protocol for a systematic review and meta-analysis will enable a comprehensive appraisal of the literature
to help determine whether overall institutional savings are associated with this approach. Findings will form a knowledge base
relevant to stakeholders across the health system and researchers who are involved in decision making on evidence-based nutrition
care plan pathways for patients undergoing esophagectomy, as well as the use of IEF, timing, and administration quantity.
Trial Registration: PROSPERO Registration Number: CRD42017056908; http://www.crd.york.ac.uk/PROSPERO/
display_record.asp? ID=CRD42017056908 (Archived by WebCite at http://www.webcitation.org/6rLyeqaD6)
(JMIR Res Protoc 2017;6(11):e214)   doi:10.2196/resprot.7688
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Introduction
Description of the Condition
Adult patients with an esophageal cancer or intractable strictures
often require resection of the esophagus with complex
anastomoses that can potentially be compromised with
postoperative leaks or fistulae if patients’ nutritional status is
in a vulnerable stage [1,2]. Additionally, pulmonary
complications, especially pneumonia, are a major component
of morbidity after an esophagectomy [3].
Although it is challenging to define and measure nutritional
status in oncology, cancer-associated malnutrition seems to
affect this population even in those overweight or well-nourished
patients with a recent diagnosis [4]. Up to 85% of patients
develop cancer-associated malnutrition, in which individual
susceptibility depends on several factors such as the type, grade,
and stage of cancer as well as the side effects of treatment
modalities [5,6]. These factors may have a negative impact
causing systemic anorexia combined with altered absorption of
nutrients, unintentional weight loss, and depletion of lean body
mass [4]. Moreover, pre-existing poor dietary habits,
socioeconomic status, functional performance, nutritional impact
symptoms, requirements for fasting, and inadequate nutritional
therapy may affect nutritional intake as well, causing a
progressive and widespread sarcopenia [6]. Because of this
nutritional depletion, the risk of morbidity and mortality
increases as well as the length of hospitalization and health care
costs [7].
Currently in Australia, there is a growing need for clinicians to
know whether the use of immune-enhancing formulas (IEFs)
containing arginine (Arg), omega-3, and ribonucleic acid (RNA)
is a cost-effective approach compared with isonitrogenous-
isocaloric formula to reduce postoperative infectious
complications (POIC) in esophagectomy patients [8]. Since
these IEFs may carry higher costs, selective and cautious use
with patients has led to inconsistencies among practitioners or
hospitals, possibly because of insufficient targeted
evidence-based guidelines advocating or supporting enteral
immunonutrition (IN) in esophageal resection patients [9].
Thus, this systematic review will enable a comprehensive
appraisal of the literature to assist in determining whether overall
institutional savings are associated with this approach. This
review also seeks to compile and present the most up-to-date
available evidence on the provision of IEFs containing Arg,
omega-3, and RNA, to help clinicians develop an evidence-based
nutrition care plan. Furthermore, we aim to identify available
evidence of whether an esophagectomy patient would be the
ideal case to receive IN, and a cost-benefit analysis to determine
appropriate administration quantity and timing (pre-, peri-, or
postesophagectomy).
We aim to address the following research questions. In cancer
patients undergoing esophageal resection and requiring
postoperative nutritional support: (1) Is there sufficient quality
evidence on perioperative IEF enriched with omega-3, Arg, and
RNA to recommend it as routine practice among clinicians?,
(2) Do IEFs enriched with omega-3, Arg, and RNA confer
additional clinical benefits such as reducing the risk of POIC
and improving patients’ health care outcomes compared to
standard enteral nutrition?, and (3) Are IEFs enriched with
omega-3, Arg, and RNA a cost-effective strategy to be
considered by clinicians?
Methods
Types of Studies
This review will include randomized controlled trials (RCTs)
on National Health and Medical Research Council level II
intervention and use of IEFs in esophagectomy patients. The
trials selected should contain IEFs (containing Arg, omega-3,
and RNA) compared with standard enteral formulas (SEFs)
either pre-, post-, or perioperative. Non-RCT intervention studies
such as cohort studies will be excluded, since the potential risk
of bias is higher. Likewise, we will exclude observational
studies, abstracts, review papers, conference proceedings, and
studies that are not English, Spanish, or Portuguese language.
Ethical approval is not required for the proposed systematic
review and meta-analysis because the data used in this review
will not involve the privacy of individual patients. Findings will
be reported in line with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) [10]. As
well, the manuscript will be submitted for publishing in a
peer-reviewed journal or the findings presented at a relevant
conference.
Types of Participants
All patients 18 years or over undergoing surgical procedure for
esophageal cancer will be included. Also, those included should
be receiving IEF (containing a combination of Arg, omega-3,
and RNA) pre-, peri-, or postoperatively for at least 5-7 days.
Moreover, we will include all inpatient and
outpatient/ambulatory patients in the health care facility where
patients are having surgery (Textbox 1).
Types of Interventions
The intervention will be the use of IEFs containing the
immunonutrients Arg, omega-3 polyunsaturated fatty acid, and
RNA provided either orally or via an enteral feeding tube. To
be included, studies will have IEF given pre-, peri-, and/or
postoperatively as an intervention. Co-intervention with other
oral or parenteral substances will not be included. The control
group should be receiving the traditional
isonitrogenous-isocaloric SEF or polymeric nutritional
supplements either orally or via enteral feeding tube.
Primary and Secondary Outcomes
Primary Outcomes
The primary outcome will be POICs including wound infections
or ﬁstulae formation, bacteremia, sepsis, anastomotic leakage,
abscess and pulmonary complications, especially pneumonia
or bronchopneumonia within the first 2 weeks of surgery and
during the whole stay in hospital [3]. The measure will be as
deﬁned by trial authors (categorical: present/absent or yes/no
or continuous as number of cases or percentage of people with
POIC).
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Textbox 1. Participant inclusion and exclusion criteria.
Inclusion criteria:
• Adult patients (≥18 years) undergoing an elective surgical procedure for esophageal cancer; perioperative patients
• Adult patients in various stages of the disease including I, II, III, and IV
• All patients (inpatient and outpatient) undergoing surgery
• Receiving perioperative IEF (Impact/other similar formulation: combination of Arg, omega-3, and RNA for at least 5-7 days)
Exclusion criteria:
• Lower GI cancer surgery, gastric, or head cancer surgery
• Patients with cancer having parenteral nutrition or enteral feeding with non-IEF or IEF with only one isolated nutrient (Arg vs omega-3 vs RNA)
Secondary Outcomes
We will consider the following secondary outcomes measured
pre- and/or postoperatively:
• Health-related costs/cost-effectiveness/cost-benefit: defined
by the authors
• Health care use: length of stay (LOS) measured in number
of days; readmissions to acute care, subacute care or
intensive care unit; re-operations measured in number of
cases
• Survival/mortality: number/proportion of deaths related to
treatment ˂18 months (long-term survival) [11];
number/proportion of deaths (≤30 days and/or in-hospital
postoperatively) [11]
• Quality of life: health-related quality of life measures via
a validated diagnostic tool such as the European
Organisation for Research and Treatment of Cealth-related
quality of life questionnaires (within the first 3, 6, and 24
weeks postoperatively [12]; including symptoms such as
eating difficulties, reflux, dysphagia, and trouble with
coughing [13]
• Nutritional status: classified as well-nourished or
malnourished and measured by validated nutrition
assessment tool within 2 weeks pre-operatively
• Percentage of weight loss: ˃5% weight loss in past month
(1/12) and 1 week and/or 3 weeks postoperatively
• Biochemical changes: as per trial authors, including
C-reactive protein levels (from ≤7 days prior surgery and
first 2 weeks postoperatively)
Searches
Searches for RCTs will be conducted systematically by the
reviewers, with no publication year restriction.
Non-English/Spanish/Portuguese studies might be excluded
unless translations were provided or arranged. Also, original
authors may be contacted for clariﬁcation and request of further
data if trial reports seem unclear. Computerized searches will
be performed for relevant published studies on the following
databases from their inception until July 2017: the Cochrane
Central Register of Controlled Trials (CENTRAL-The Cochrane
Library), PubMed, EMBASE, CINAHL, LILACS,
ClinicalTrials.gov, and the Trip (Turning Research into Practice)
database. Subject strategies for databases in the search strategy
will be modeled and designed for CENTRAL, CINAHL, and
PubMed (Multimedia Appendix 1), which can be adjusted for
other databases. Where appropriate, subject strategies will be
combined with adaptations of the highly sensitive search strategy
for identifying RCTs as described in the Cochrane Handbook
for Systematic Reviews of Interventions Version 5.1.0 [14].
Additionally, during the searching process, consideration will
be given to the different terminology used and the spelling of
keywords as they may influence the identification of relevant
studies.
The reference lists of identiﬁed publications will be scanned
for further trials, and some trial authors may be contacted if
required. Additional searches with Google Scholar, Google,
and Bond University Library online will be conducted to retrieve
remaining systematic reviews and meta-analyses pertinent to
this review, in order to scan their reference lists for additional
existing trials. A search of gray literature may be performed
using the and .
Data Collection and Analysis
Selection of Studies
The results of the searches will be combined as indicated in
Multimedia Appendix 1. The titles and abstracts identified from
the search will be screened and assessed independently by the
reviewers against the inclusion criteria to remove those that are
inappropriate. If the title or abstracts are inconclusive, further
in-depth screening and evaluation against the inclusion criteria
will be undertaken. The reviewers will record independently
the reasons for study exclusion and will report them in a flow
diagram according to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) format [10].
Disagreements over study selection will be resolved by
discussion, and an external person may arbitrate if needed. Trial
investigators shall be contacted if further information is required.
All eligible references will be entered/collected into the
bibliographic software package EndNote.
Data Extraction and Management
Data such as study design and setting, number of participants,
outcome measure, and timing of IN initiation, route feeding,
and total duration of IN will be autonomously extracted and
organized on a matrix table (Multimedia Appendix 2). The
meta-analysis data will also be pooled and organized on a matrix
table (Multimedia Appendix 3). Reviewers will reach a
consensus view by discussion. If further information is needed
from an RCT, one of the reviewers may contact the nominated
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trial investigator/author. A plan of how data will be pooled and
organized for the outcome measures analysis is shown in
Multimedia Appendix 4.
Assessment of Risk of Bias
The risk of bias in the eligible studies will be independently
assessed by the reviewers. Any disagreements will be resolved
through discussion with an external arbitrator if required. Risk
of bias assessment will be performed using the domain-based
evaluation tool described by the  Cochrane Handbook for
Systematic Reviews of Interventions [14].
Every RCT will be appraised according to the quality of 6
domains: (1) random sequence generation and allocation
concealment (selection bias), (2) blinding of participants and
personnel (performance bias), (3) blinding of outcome
assessment (detection bias), (4) incomplete outcome data
(attrition bias), (5) selective reporting (reporting bias), and (6)
any other potential concerns to validity [14]. Blinding will be
assessed separately for subjective (eg, nutritional status, LOS,
quality of life) and objective (eg, percentage of weight loss,
biochemical/immunological changes, mortality) outcome
measures as the latter are less likely to be affected by knowledge
of the treatment allocation group. Publication bias will be
visually assessed by funnel plots as indicated by PRISMA [10].
Based on study reports, preliminary information will be collected
in matrix tables to inform the risk of bias assessments
(Multimedia Appendix 2). Trial authors shall be contacted to
provide a study protocol or to clarify uncertainties where
inconsistencies or unclear methodology were present during the
risk of bias assessment.
A low risk of bias RCT will be considered if all or the majority
of domains were gauged as adequate. RCTs will be considered
as having a high risk of bias when one or more of the assessed
domains within that trial were unclear or inadequate (unless
original authors answer queries otherwise). The “risk of bias or
internal validity” will be reported as part of the “characteristics
and outcomes of identified studies” matrix (Multimedia
Appendix 2) as well as a “risk of bias summary ﬁgure”
presenting detailed judgments or explanations for all included
studies in this review [2].
Data Analysis and Synthesis
Categorical data will be presented as risk ratio and risk
difference or odds ratio including their 95% confidence intervals
(CI), which will be calculated/extracted for the analysis of most
of the outcome measures apart from health care use (ie, LOS)
and biochemical/immunological changes that are exclusively
represented as continuous variables (Multimedia Appendix 4).
Also, numbers needed to treat for beneﬁt or harm could be
calculated as needed. Continuous data will be presented as mean,
mean difference, or standardized mean difference with 95% CI,
as applicable, excluding the nutritional status outcome measure,
as it is represented exclusively as dichotomous variable. If a
specific study does not report standard deviations, these will be
calculated from the standard error and the sample size or the
95% CI. Finally, a P value of <.05 for both continuous and
dichotomous variables will be considered statistically significant
(Multimedia Appendix 4).
Assessment of Heterogeneity
Heterogeneity must be considered from both a clinical and
statistical perspective. On one hand, clinical expertise will be
used to decide whether it would be meaningful to combine the
studies based on the potential sources of heterogeneity for each
outcome measure. The potential sources where the RCTs may
not show the exact same result could depend on factors such as
the patients’ demographics (eg, age: adult vs elderly), nutritional
status baseline, type of surgery (invasive or less invasive),
different doses and timing of pre- versus peri- versus
postoperative IEF, definition of the outcome measures, as well
as the timing for measuring those outcomes (Multimedia
Appendix 5). Hence, clinical heterogeneity will be reported
using subgroup (pre-, peri-, and postoperative subgroups using
IEF; well-nourished vs malnourished patients’ subgroups).
Sensitivity analysis might also be calculated by restricting the
analysis to trials classified as having an overall low risk of bias,
which will help determine whether excluding studies at high
risk of bias affects the results of the meta-analysis [13,15,16].
On the other hand, statistical heterogeneity, which quantifies
the variation due to heterogeneity and not due to chance across
the RCTs, will be also checked through the statistical calculation
of an I2 test [2]. Hence, values of 25%, 50%, or 75% will denote
low, moderate, or high levels of heterogeneity respectively [2].
After that process, if the degree of clinical and statistical
heterogeneity of studies are not excessive, a quantitative
summary measures (meta-analysis) will be generated by the
Review Manager (RevMan) 5.3 software and represented in
forest plots [14]. Thus, the meta-analysis will characterize the
effect of the dichotomous and continuous outcomes.
Where statistical pooling is not possible, the findings will be
presented in narrative form or a table to describe the outcomes,
different tools used to assess the outcomes listed for this review,
or continuous data that can be pooled for meta-analysis.
Confidence in Cumulative Estimate
The quality of evidence for all outcomes will be judged using
the Grading of Recommendations Assessment, Development
and Evaluation working group methodology. Therefore, the
quality of evidence will be assessed across 5 domains: risk of
bias, consistency, directness, precision, and publication bias.
Additional domains may be considered where appropriate.
High-quality evidence will be adjudicated when further research
might be very unlikely to change the reviewer’s confidence in
the estimate of effect; moderate quality if further research is
likely to have a significant impact on the confidence and may
change the estimate; low quality if further research is needed
and is very likely to have an important impact and likely to
change the estimate; and very low quality if there is considerable
uncertainty about the estimate of effect.
Results
The first results are expected in 2018. Outlining the protocol
will ensure transparency for the completed review.
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Discussion
Principal Considerations
Given the nature of esophageal cancer and the significant
potential for nutritional deficiencies prior to resection as
compared with other gastrointestinal (GI) pathologies, it seems
appropriate that there should be a specific focus on the role of
perioperative nutritional supplementation [17]. Research has
shown that IEFs enriched with a combination of Arg, omega-3
fatty acids, including eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), RNA, and antioxidants [18], can
act pharmacologically on the immune system and potentially
improve the patient’s immune response [9]. Furthermore,
providing patients with peri-operative IEF has shown to
favorably modulate the inﬂammatory, metabolic, and immune
response after upper GI surgery [19,20]. These effects generated
on the immune system modulated through specific nutrients are
called immunonutrition.
IEFs enriched with a combination of immunonutrients (Arg,
omega-3, and RNA) are well known to Australian clinicians.
However, IN is not consistently used with cancer patients
undergoing esophageal resection as standard practice [21]. Since
this IEF offers the combination of immunonutrients in one
product, it has been implemented in a wide range of surgical
and trauma patients [22] to significantly reduce POICs by
39%-61%, LOS by 2 days [23], antibiotic use, and health-related
costs [18]. Several studies have shown positive outcomes among
GI surgical patients, where anastomotic leaks were 46% less
prevalent when these IEFs were part of the pre-operative
nutrition care plan [3,18,21,23,24]. Additionally, it has been
found that LOS and POIC in malnourished (upper and lower)
GI cancer patients significantly decreased when a “5-7-day
peri-operative approach” was implemented with IEF over SEF
[18,25,26]. Thus, nutrition support of surgical patients with
malnutrition should not only include the adequate quantity but
also the nutrient quality, type, and prescription timeframe to
support the patient’s recovery, postoperative outcomes, and
reduce health care costs [20,27-29]. In terms of health care
cost-benefit analysis, the implementation of IN in surgical
patients resulted in savings of US $3300 per patient based on
the reduction of POIC rates [22] and reported savings of up to
US $6000 per patient, based on the shortening of LOS [16],
showing that enteral IEFs are a beneficial and cost-effective
intervention.
Conclusion
To date, there have been several systematic reviews and
meta-analyses of RCTs undertaken to determine the
effectiveness of IN in elective upper and lower GI surgical
practice [7,16,21,30]. However, the effect of a particular
combination of immunonutrients (Arg, omega-3, and RNA) and
its overall effect on postesophagectomy outcomes have not been
systematically reviewed. Hence, there is a lack of sufficient,
recent clinical evidence supporting the use of IEFs in
esophagectomy patients. Evaluation of the studies identiﬁed in
this review has merit because the review will aim to provide
the most up-to-date evidence-based nutrition statements
regarding pre-, peri-, and postoperative enteral IN effects on
postesophagectomy outcomes.
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